Pure Global
NCT05966753

Describing Patient With DME, Their Patient Journey and Disease Progression

Observational Study on the Management, and Progression of Patients With Diabetic Macula Edema (DME)
Boehringer Ingelheim·ClinicalTrials.govNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Diabetic Macular Edema
Study type
Observational
Sponsor & location
Primary sponsor
Boehringer Ingelheim
Timeline & enrollment
Phase
N/A
Start date
Jul 31, 2023
End date
Sep 30, 2023
Enrollment
182000 participants
Primary outcome

Change in visual acuity,Progression to DME in the fellow eye,Initial treatment of DME,Central retinal thickness (CRT)

Summary

This study aims to characterize patients with diabetic macular edema (DME), their
 progression, the treatment received and associate the functional and physiological outcomes
 related to the treatment.

ICD-10 classifications
Diabetic retinopathyOther specified diabetes mellitus with ophthalmic complicationsUnspecified diabetes mellitus with ophthalmic complicationsDiabetic cataractType 2 diabetes mellitus with ophthalmic complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05966753
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05966753 through Pure Global AI's free database. This phase not specified trial is sponsored by Boehringer Ingelheim and is currently Not yet recruiting. The study focuses on Diabetic Macular Edema. Target enrollment is 182000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.